This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Tyrrell, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Tyrrell, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2001, p. 2363-2367, Vol. 45, No. 8
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.8.2363-2367.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activities of ABT-773, a New Ketolide, against Aerobic and Anaerobic Pathogens Isolated from Antral Sinus Puncture Specimens from Patients with Sinusitis

Ellie J. C. Goldstein,1,2,* Georg Conrads,1,3 Diane M. Citron,1 C. Vreni Merriam,1 Yumi Warren,1 and Kerin Tyrrell1

R. M. Alden Research Laboratory Santa Monica-UCLA Medical Center, Santa Monica, California 904041; UCLA School of Medicine, Los Angeles, California 900732; and Institute of Medical Microbiology, University of Aachen (RWTH), Aachen, Germany3

Received 2 April 2001/Accepted 4 May 2001

The comparative in vitro activities of ABT-773 against 207 aerobic and 162 anaerobic antral sinus puncture isolates showed that erythromycin-resistant pneumococcal strains were susceptible to ABT-773 (<= 0.125 µg/ml); the MIC at which 90% of the isolates tested were inhibited for Haemophilus influenzae and other Haemophilus spp. was 4 µg/ml; and all Moraxella spp. and beta-lactamase-producing Prevotella species strains were inhibited by <= 0.125 µg/ml. Among the anaerobes tested, only fusobacteria (45%) required >= 4 µg of ABT-773/ml for inhibition. ABT-773 may offer a therapeutic alternative for sinus infections.

* Corresponding author. Mailing address: 2021 Santa Monica Blvd., Suite 740 East, Santa Monica, CA 90404. Phone: (310) 315-1511. Fax: (310) 315-3662. E-mail: EJCGMD{at}aol.com.

Antimicrobial Agents and Chemotherapy, August 2001, p. 2363-2367, Vol. 45, No. 8
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.8.2363-2367.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Conte, J. E. Jr., Golden, J. A., Kipps, J., Zurlinden, E. (2004). Steady-State Plasma and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Cethromycin. Antimicrob. Agents Chemother. 48: 3508-3515 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»